Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05388773 · ClinicalTrials.gov registry record · Phase 2
Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
A Phase 2 study of Oropharynx Cancer, sponsored by Heath Skinner.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT05388773 is a Phase 2 study of Oropharynx Cancer that is actively recruiting participants, run by Heath Skinner. The registered enrollment target is 150 participants, above the 126-participant average among 26 other Oropharynx Cancer trials with a reported enrollment target (19% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05388773, a Phase 2 study of Oropharynx Cancer, is actively recruiting participants, sponsored by Heath Skinner.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a trial studying patients with human papilloma virus (HPV) positive oropharyngeal cancer with tumors that can be removed via transoral surgery. Following surgery, patients will be classified as either low, intermediate, or high risk based on the characteristics of the tumors. Low risk patients (Arm S) will receive no further treatment after surgery. Intermediate risk patients (Arm RT) will be treated with Intensity Modulated Radiotherapy (IMRT) after surgery. High risk patients (Arm CRT) will receive a combination of IMRT and chemotherapy after surgery. Patients will be followed for up to five years after the completion of treatment.
Conditions Studied
Interventions
- DRUG Cisplatin
- OTHER laboratory biomarker analysis
- PROCEDURE therapeutic conventional surgery
- OTHER quality-of-life assessment
- RADIATION intensity-modulated radiation therapy
Study Locations (1)
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2022-07-20 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05388773
The ClinicalTrials.gov registry entry for NCT05388773 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 126-participant average among 26 other Oropharynx Cancer trials with a reported enrollment target (19% higher). The listed sponsor is Heath Skinner, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Oropharynx Cancer appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.
NCT05388773 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05388773 about?
NCT05388773 is a clinical study titled "Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer". This is a trial studying patients with human papilloma virus (HPV) positive oropharyngeal cancer with tumors that can be removed via transoral surgery. Following surgery, patients will be classified as either low, intermediate, or high risk based on the characteristics of the tumors. Low risk patien...
What is the current status of trial NCT05388773?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2022-07-20. Estimated completion is 2030-12-31.
What conditions does trial NCT05388773 study?
This clinical trial studies the following conditions: Oropharynx Cancer.
What interventions are being tested in trial NCT05388773?
The interventions under investigation include: Cisplatin (DRUG), laboratory biomarker analysis (OTHER), therapeutic conventional surgery (PROCEDURE), quality-of-life assessment (OTHER), intensity-modulated radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT05388773?
This trial is sponsored by Heath Skinner, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05388773 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oropharynx Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)
RECRUITING · Phase 2
-
Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
RECRUITING · Phase 2
-
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.